Scynexis Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp ' s Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials